Valuation: Autolus Therapeutics plc

Market Cap 428M 376M 349M 321M 606M 40.97B 619M 4.16B 1.63B 20.13B 1.61B 1.57B 69.59B P/E 2026 *
-1.67x
P/E 2027 * -2.36x
Enterprise Value 389M 342M 317M 291M 550M 37.19B 562M 3.78B 1.48B 18.27B 1.46B 1.43B 63.17B EV / Sales 2026 *
3.03x
EV / Sales 2027 * 2.5x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 day-8.07%
1 week-6.33%
Current month-7.50%
1 month-5.13%
3 months-0.67%
6 months-1.33%
Current year-25.63%
1 week 1.48
Extreme 1.48
1.74
1 month 1.46
Extreme 1.46
1.74
Current year 1.18
Extreme 1.175
2.07
1 year 1.18
Extreme 1.175
2.7
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 31/08/2014
Chief Executive Officer 61 29/02/2016
Director of Finance/CFO 56 06/08/2023
Director TitleAgeSince
Chairman 61 30/09/2014
Director/Board Member 78 31/07/2014
Director/Board Member 71 28/02/2018
Date Insider Type Main position Quantity % Market Cap.
06-28Free

Director

79,167 0.0477%
06-28Free

Director

79,167 0.0477%
06-28Free

Chairman

79,167 0.0477%
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-6.33%-40.08%-41.04% 428M
-0.22%+1.35%+16.79%-7.70% 67.61B
-0.63%-9.21%+37.82%+200.20% 51.6B
+0.36%+40.00%+40.00%+40.00% 43B
-1.26%-0.39%-49.63%-53.84% 40.94B
+4.96%-3.28%+55.75%-24.71% 29.4B
-1.85%-15.99%+99.20%-46.78% 27.09B
-2.12%-2.25%+66.54%+82.33% 23.32B
-0.67%+1.48%+10.61%+188.35% 19.92B
-2.12%-3.72%+61.37%+126.08% 16.91B
Average -0.89%-2.77%+29.84%+46.29% 32.02B
Weighted average by Cap. -0.05%-3.05%+30.87%+47.21%

Financials

2026 *2027 *
Net sales 129M 113M 105M 96.32M 182M 12.29B 186M 1.25B 488M 6.04B 483M 472M 20.88B 191M 168M 156M 143M 270M 18.26B 276M 1.85B 725M 8.97B 717M 701M 31.02B
Net income -241M -212M -197M -181M -342M -23.09B -349M -2.35B -917M -11.34B -907M -887M -39.22B -184M -161M -150M -138M -260M -17.57B -265M -1.78B -698M -8.63B -690M -675M -29.84B
Net Debt -39.53M -34.73M -32.19M -29.62M -55.95M -3.78B -57.13M -384M -150M -1.86B -148M -145M -6.42B 48.41M 42.53M 39.43M 36.27M 68.52M 4.63B 69.97M 470M 184M 2.27B 182M 178M 7.86B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
13/07/26 US$1.480 -8.07% 2,088,666
10/07/26 US$1.610 -4.73% 1,348,300
09/07/26 US$1.690 -0.59% 1,111,045
08/07/26 US$1.700 +5.59% 1,673,442
07/07/26 US$1.610 -1.23% 755,323
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.610USD
Average target price
8.550USD
Spread / Average Target
+431.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock